The Second Drug That Changed Thyroid Eye Disease: What Lumvoa's Approval Means for Patients and the Market

For most of the past six years, thyroid eye disease had exactly one approved systemic treatment. Tepezza, the teprotumumab infusion developed by Horizon Therapeutics and now owned by Amgen, transformed the field when it received FDA approval in 2020. Before Tepezza, patients with the disfiguring orbital inflammation that defines TED had limited options: steroids, radiation, and in severe cases, decompression surgery. Tepezza changed that calculus, and the drug became one of the most commercially successful rare disease launches in recent memory, generating roughly two billion dollars in annual sales. For five years, it stood alone.

That changed on June 26, 2026, when the FDA approved Lumvoa (veligrotug-vvze), developed by Viridian Therapeutics, for the treatment of thyroid eye disease. The approval is not simply the arrival of a second drug in a class. It is the arrival of a drug with a meaningfully different clinical profile, one that addresses a gap Tepezza's label never fully closed and that positions Viridian to compete in a market that analysts project will reach four billion dollars by 2034.

What Lumvoa Is and How It Works

Like Tepezza, Lumvoa targets the insulin-like growth factor-1 receptor, or IGF-1R, a protein expressed on orbital fibroblasts that plays a central role in the inflammatory cascade driving TED. The cross-talk between IGF-1R and the thyroid-stimulating hormone receptor is the mechanistic foundation of the disease, and blocking IGF-1R has proven to be a clinically validated approach. What distinguishes Lumvoa is that it is a full antagonist of IGF-1R, meaning it completely blocks receptor signaling rather than partially inhibiting it. Whether that pharmacological distinction translates into a clinically meaningful difference in outcomes compared to Tepezza is a question that head-to-head data, which do not yet exist, would need to answer. But the clinical trial results that supported the approval are compelling on their own terms.

Lumvoa is administered as five intravenous infusions given every three weeks over a 12-week course. The FDA approval was supported by two pivotal Phase 3 trials: THRIVE, which enrolled patients with active TED, and THRIVE-2, which enrolled patients with chronic TED. Both trials met their primary and all secondary endpoints at week 15, with statistically significant and clinically meaningful improvements across the key signs and symptoms of the disease. Proptosis reductions, the reduction in the forward protrusion of the eye that is one of TED's most visible and distressing features, were observed as early as week three.

The Chronic Disease Distinction That Matters

The most strategically significant element of Lumvoa's approval is its label. Viridian's drug is the first approved treatment for TED with labeling that includes data for both active and chronic disease. Tepezza's label is primarily supported by data in active TED, the phase of the disease characterized by ongoing inflammation and a Clinical Activity Score above a defined threshold. Chronic TED, in which the active inflammatory phase has resolved but structural changes and symptoms persist, represents a substantial portion of the patient population. Physicians treating patients in the chronic phase have had limited evidence-based options, and the question of whether IGF-1R inhibition could help those patients has been a persistent gap in the field.

Lumvoa is also the first approved product for TED to show a statistically significant effect on both diplopia response rate and complete resolution of diplopia in both active and chronic disease. Diplopia, or double vision, is one of the most functionally debilitating symptoms of TED, and its resolution is a meaningful clinical outcome for patients whose daily lives are disrupted by the inability to see clearly. The fact that Lumvoa demonstrated this effect across both disease phases, not just in the active setting, gives prescribers a clinical rationale for its use in a broader population than Tepezza's label has historically supported.

The Competitive Dynamics and What They Mean

Viridian's entry into the TED market creates a competitive dynamic that will play out over the next several years in ways that are not yet fully predictable. Amgen, which acquired Tepezza as part of its 27.8 billion dollar purchase of Horizon Therapeutics in 2023, has a dominant commercial position and a well-established prescriber base. Tepezza's hearing loss signal, which has shaped prescribing patterns and generated significant patient concern, is a known liability that Viridian has positioned Lumvoa against. Lumvoa's own label includes a hearing impairment warning, consistent with the broader IGF-1R inhibitor class, so the differentiation on this dimension is not absolute. But the chronic TED label and the diplopia data give Viridian a genuine clinical story to tell.

The more interesting competitive question may be what comes next from Viridian's own pipeline. The company is advancing elegrobart, a subcutaneous investigational IGF-1R therapy, with a biologics license application submission targeted for the first quarter of 2027. A subcutaneous formulation would represent a meaningful convenience improvement over the intravenous infusion that both Lumvoa and Tepezza require, and if elegrobart's clinical data are strong, it could further differentiate Viridian's position in the market. The company is essentially building a TED franchise, with Lumvoa as the first commercial product and elegrobart as the next potential advance.

What This Means for Patients and the Field

TED affects an estimated 200,000 people in the United States, most of them women with Graves disease or other autoimmune thyroid conditions. The disease is not simply a cosmetic problem. The proptosis, diplopia, periorbital pain, and in severe cases compressive optic neuropathy that TED produces can cause significant functional impairment and profound psychosocial distress. Patients describe the experience of watching their appearance change, of losing the ability to see clearly, and of navigating a medical system that for decades had little to offer beyond managing the consequences of the disease rather than treating its cause.

The arrival of a second approved therapy in this space is meaningful for reasons that go beyond market competition. It validates the IGF-1R pathway as a durable therapeutic target, creates the conditions for genuine clinical differentiation between agents, and gives physicians and patients a choice that did not previously exist. Competition in rare disease markets tends to drive access improvements, patient support programs, and pricing pressure over time, all of which benefit the people who need these drugs. Viridian has already announced ViridianCares, a comprehensive patient support program designed to help patients navigate insurance coverage and financial assistance.

The TED treatment landscape that existed before 2020 was defined by the absence of targeted therapy. The landscape that exists today, with two approved IGF-1R inhibitors and a subcutaneous candidate in late-stage development, is a different kind of field entirely. For patients who have been waiting for options, and for physicians who have been managing a disease with inadequate tools, that transformation is the story worth telling.